Original title: Reduction in Cardiac Mortality with Bivalirudin in Patients With and Without Major Bleeding: The HORIZONS-AMI Trial. Reference: Gregg W. Stone et al. J Am Coll Cardiol. Epub ahead of print The HORIZONS -AMI study included 3602 patients experiencing ST segment elevation myocardial infarction received primary angioplasty, resulting in lower mortality at 30 days and three years<a href="https://solaci.org/en/2013/10/21/low-cardiac-mortality-with-bivalirudin-beyond-the-reduction-in-major-bleeding/" title="Read more" >...</a>
Infarct size reduction to 30 days could result in clinical benefit at one year
Original title: Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: One-year results from the INFUSE-AMI trial. Reference: Stone GW et al. Circ Cardiovasc Interv. 2013;Epub ahead of print. The intra-coronary infusion of Abciximab added to thromboaspiration seems to improve outcomes at one year in patients undergoing primary angioplasty for ST-segment elevation with anterior<a href="https://solaci.org/en/2013/10/16/infarct-size-reduction-to-30-days-could-result-in-clinical-benefit-at-one-year/" title="Read more" >...</a>
Noncardiac surgery is safe after 6 months after implantation of a DES
Original title: Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. Reference: Hawn MT et al. JAMA 2013;DOI:10.1001 In the patients who underwent non cardiac surgery and had coronary angioplasty with stent history within 2 years there was not increased in major cardiac events (MACE ) with the exception of those who were<a href="https://solaci.org/en/2013/10/11/noncardiac-surgery-is-safe-after-6-months-after-implantation-of-a-des/" title="Read more" >...</a>
Cilostazol reduces restenosis of DES in lesions larger than 40 mm.
Original title: Comparison of Dual Versus Triple Antiplatelet Therapy After Drug-Eluting Stent According to Stent Length (from the Pooled Analysis of DECLARE Trials). Reference: Seung-Whan Lee et al. Am J Cardiol 2013, article in press. Cilostazol, an inhibitor of phosphodiesterase III , associated with aspirin and clopidogrel showed decrease angiographic restenosis both in conventional stents as well as<a href="https://solaci.org/en/2013/10/07/cilostazol-reduces-restenosis-of-des-in-lesions-larger-than-40-mm/" title="Read more" >...</a>
Ticagrelor effective in venous bridges
Original title: Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass grafo surgery: Inssights from th PLATelet inhibition and patients outcomes (PLATO) trial. Reference: Emmanouil S. Brilakis, et al. Am Heart J 2013;166:474-80 The bridge venous occlusion is a common finding in patients with previous CABG presenting with acute coronary syndrome without ST<a href="https://solaci.org/en/2013/09/27/ticagrelor-effective-in-venous-bridges/" title="Read more" >...</a>
Paclitaxel eluting balloon . More effective in restenosis of BMS than DES
Original title: A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Referencia: Seiji Habara et al. Am Heart J 2013;166:527-533.e2. Paclitaxel – eluting balloons have recently emerged as an option for treating in-stent restenosis, both conventional stents ( BMS ) and with drugs (DES ).<a href="https://solaci.org/en/2013/09/25/paclitaxel-eluting-balloon-more-effective-in-restenosis-of-bms-than-des/" title="Read more" >...</a>
Usefulness of FFR in coronary bypass intermediate lesions
Original title: Long-term clinical outcome after fractional flow reserve– versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. Reference: Luigi Di Serafino et al. Am Heart J 2013;166:110-8. Bypass coronary angioplasty is often preferred strategy versus re-operation , however it is associated with a greater number of events, both short and long<a href="https://solaci.org/en/2013/09/24/usefulness-of-ffr-in-coronary-bypass-intermediate-lesions/" title="Read more" >...</a>
Everolimus Eluting Stent in multiple vessels with short SYNTAX score
Original title: A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With Multivessel Coronary Artery Disease. The EXECUTIVE (EXecutive RCT: Evaluating XIENCE V in a Multi Vessel Disease) Trial. Reference: Flavio Ribichini et al. J Am Coll Cardiol Intv 2013. Article in press. Drug-eluting stents (DES ) have emerged<a href="https://solaci.org/en/2013/09/24/everolimus-eluting-stent-in-multiple-vessels-with-short-syntax-score/" title="Read more" >...</a>
Sub intimal recanalization of superficial femoral , femoropopliteal bypass similar results
Original title: Subintimal Recanalization Plus Stenting or Bypass for Management of Claudicants with Femoro-popliteal Occlusions. Reference: Boufi et al. Eur J Vasc Endovasc Surg. Volume 46 Issue 3 September/2013. The main criticism of sub intimal technique is its relative low permeability compared to the surgical technique . Different studies reported a permeability between 56 and 70 % annually .<a href="https://solaci.org/en/2013/09/19/sub-intimal-recanalization-of-superficial-femoral-femoropopliteal-bypass-similar-results/" title="Read more" >...</a>
Ticagrelor reduces in-stent thrombosis in patients with acute coronary syndromes
Original title: Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: An analysis from the prospective randomized PLATO trial. Reference: Steg PG et al. Circulation. 2013; Epub ahead of print The PLATO study randomized 18624 patients with acute coronary syndrome to receive ticagrelor (180 mg loading dose followed by 90 mg twice daily )<a href="https://solaci.org/en/2013/09/12/ticagrelor-reduces-in-stent-thrombosis-in-patients-with-acute-coronary-syndromes/" title="Read more" >...</a>